Salvat Secures FDA Approval for Clotic®, the First Targeted Therapy for Otomycosis with Orphan Drug Designation

SALVAT receives FDA approval for Clotic®, an innovative treatment for otomycosis with Orphan Drug Designation     Th...

October 22, 2025 | Wednesday | News
Genentech’s Gazyva® Receives FDA Approval for the Treatment of Lupus Nephritis in Adults

 The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by Genentech, as a treatment for adults with lupus n...

October 21, 2025 | Tuesday | News
Adcytherix Raises €105 Million Series A to Advance Next-Generation Antibody–Drug Conjugates with Novel Payloads

Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads Financing led b...

October 20, 2025 | Monday | News
Azurity Pharmaceuticals Receives FDA Approval for Ferabright™, the First Iron-Based MRI Contrast Agent for Brain Tumour Imaging

Azurity Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved FerabrightTM (ferumoxytol injection), the first and...

October 20, 2025 | Monday | News
French Biotech EVerZom Raises €10 Million to Launch First Clinical Trial of Exosome Therapy EVerGel™

Through this funding round, the company will initiate the clinical development of its first therapeutic candidate, EVerGel, in 2026, and will enhance its...

October 16, 2025 | Thursday | News
Corventum Secures FDA Clearance for IND of CVT-130 to Prevent Chemotherapy-Induced Cardiotoxicity

-Corventum, Inc., a new medicines company advancing novel therapies to make existing cancer treatments safer and more effective,  announced the clea...

October 15, 2025 | Wednesday | News
Excellergy Launches with $70M Series A to Redefine Allergy Treatment with First-in-Class Trifunctional ECRIs

-Redefining Allergy Treatment with New Class of Trifunctional ECRIs designed to deliver powerful efficacy, rapid relief and complete control of alle...

October 14, 2025 | Tuesday | News
Bicara Therapeutics’ Ficerafusp Alfa Receives FDA Breakthrough Therapy Designation for HPV-Negative Head and Neck Cancer

Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patien...

October 14, 2025 | Tuesday | News
Gelteq Partners with Melbourne Health to Develop Innovative Oral Gel Product for Bowel Polyp Prevention

Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solution...

October 10, 2025 | Friday | News
MannKind Completes Acquisition of scPharmaceuticals to Strengthen Cardiometabolic Portfolio and Accelerate Growth

MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc. The acquisition of scPhar...

October 08, 2025 | Wednesday | News
Invivyd Receives FDA Clearance to Advance REVOLUTION Program with Phase 3 DECLARATION and LIBERTY Trials for COVID Prevention

The DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID vaccination) clini...

October 07, 2025 | Tuesday | News
Leo Cancer Care Partners with TibaRay to Power Next-Gen Upright Radiotherapy with Advanced Linac Technology

Leo Cancer Care announced that it has placed orders for TibaRay's advanced linear accelerators (linacs), which will be evaluated as an upgrade option to th...

October 06, 2025 | Monday | News
Draig Therapeutics Secures FDA Clearance to Launch Phase 2 Trial of DT-101 for Major Depressive Disorder

DT-101 is designed to allow effective modulation of the AMPA receptor without compromising safety Phase 2 clinical trial initiation anticipated before...

October 03, 2025 | Friday | News
BMS’s BMS-986446 Receives FDA Fast Track Designation for Early Alzheimer’s Therapy

Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease Fas...

October 02, 2025 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close